Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07298447) titled 'Donidalorsen Treatment in Children With Hereditary Angioedema' on Dec. 19, 2025.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ionis Pharmaceuticals, Inc.
Condition:
Hereditary Angioedema (HAE)
Intervention:
Drug: Donidalorsen
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: January 2026
Target Sample Size: 20
To know more, visit https://clinicaltrials.gov/study/NCT07298447
Published by HT Digital Content Services with permission from Healt...